All stories by Sushmi Dey
All life-saving drugs may come under price capRediff.com25 Oct 2014
NPPA suggests expanding the list of essential medicines whose prices are controlled
Ranbaxy staff get pay-cut shield in Sun buyoutRediff.com20 Oct 2014
Sun maintained it would retain the best of both organisations to build a global pharma company.
Ranbaxy's top executives in the US resignRediff.com14 Oct 2014
US country head, key departmental heads leave; more likely to follow.
Is India ready to fight Ebola? NO WAY!Rediff.com10 Oct 2014
No Ebola case detected in the country so far; experts say a robust preparedness plan to fight the virus missing.
Pharma firms to be hit as drug regulator caps pricesRediff.com19 Sep 2014
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
Gilead to allow 5 Indian firms to sell hepatitis generics in 90 countriesRediff.com15 Sep 2014
Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.
Sun Pharma draws up plan to fix ailing RanbaxyRediff.com12 Sep 2014
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
Drug price monitoring cells across states soonRediff.com8 Sep 2014
The idea is to keep a close watch on real-time price movements, the maximum retail price of medicines and their availability.
FDI policy for medical devices on the cardsRediff.com31 Aug 2014
Ministerial consultations on, with recognition of the potential, and the need to not classify it under the same rules as for pharmaceuticals.
Another big blow for RanbaxyRediff.com22 Aug 2014
Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.
US FDA India head quits; regulator goes for rejigRediff.com21 Jul 2014
Altaf Ahmed Lal, country head of the US Food and Drug Administration (US FDA) in India, has quit and so have a few other key officials at the American drug regulator's India office.
Sun, Ranbaxy hire Mckinsey for merger assistanceRediff.com18 Jul 2014
Sun-Ranbaxy are keen to complete the merger process.
Drug makers seek out-of-court settlement in clinical trial casesRediff.com10 Jun 2014
In a letter to health minister Harsh Vardhan, the Indian Pharmaceutical Alliance, an industry body representing leading pharma companies, including Sun Pharma, Lupin, Dr Reddy's Labs, Cadila Health and Glenmark, stressed the need for an out-of-court settlement with health activists fighting for the rights of clinical trial participants.
Drug makers told to give pricing details in 10 daysRediff.com6 Jun 2014
The Drug (Prices Control) Order implemented in May last year brought into its purview 652 packs of 348 formulations.
Now, buy medicines and stents on EMIRediff.com5 Jun 2014
The company did not respond to specific queries on the project's expansion.
Indian drug cos to benefit as US expedites generic clearancesRediff.com12 May 2014
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
Novartis-Glaxo deal signals pharma firms don't have it easyRediff.com24 Apr 2014
Experts say despite it being a global deal, the transaction will have to undergo CCI scrutiny because of the scale of operations.
Novartis-GSK-Eli Lilly deal may affect Indian marketRediff.com23 Apr 2014
On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.
ICAI to ban three auditors in Satyam caseRediff.com23 Apr 2014
ICAI has also imposed a fine of Rs 5 lakh on each of the three accused in Satyam case.
Ranbaxy buy in line with Sun's strategyRediff.com17 Apr 2014
The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.
Regulatory pain for GSK's Crocin AdvanceRediff.com28 Mar 2014
The NPPA letter was issued to GSK on Wednesday.
Consumers may have to pay more for insulinRediff.com21 Mar 2014
Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.
24 private hospitals get showcause noticesRediff.com20 Mar 2014
What started as a mere payment delay seems to have grown into a tussle between the government and leading private hospitals, empanelled under the Central Government Health Scheme.
Why is Novartis likely to lose Tiamulin drug licence?Rediff.com19 Mar 2014
Legal experts and official sources said the alleged submission of fake documents can also lead to criminal charges against Novartis.
US regulator urges USV to probe staff for inaccurate data reportingRediff.com5 Mar 2014
The US Food and Drug Administration has asked USV to probe employees who might have been responsible for inaccurate data reporting.
Why is DLF again under competition watchdog's scanner?Rediff.com4 Mar 2014
CCI has accused realty player DLF of preparing one-sided agreement with home buyers
Ranbaxy whistle-blower to talk on quality of Made-in-India drugsRediff.com27 Feb 2014
Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.
Scanner on Novartis for giving 'fake' documentsRediff.com10 Feb 2014
Swiss drug maker Novartis might face tough action from the country's drug regulator for allegedly giving fake documents while seeking renewal of registration for Tiamulin Hydrogen Fumerate (80 per cent granules), sources said.
After ban on drug facilities, US regulator comes callingRediff.com10 Feb 2014
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
US FDA's action triggers internal conflict at Ranbaxy plantRediff.com1 Feb 2014
Ranbaxy is facing trouble with its leadership, which has allegedly failed to reach out to its employees working on the ground.
Indian drug regulator threatens to ban RanbaxyRediff.com29 Jan 2014
A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.
Drug regulator lets pharma firms fix own penaltyRediff.com20 Jan 2014
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
After Ajay Devgn, Kamal Haasan approaches CCIRediff.com14 Jan 2014
Kamal Haasan has filed a complaint with the Competition Commission of India (CCI) against the Tamil Nadu Theatre Owners Association wifor restricting the release of his film Vishwaroopam in theatres last year.
Wockhardt's review petitions on drug pricing rejectedRediff.com13 Jan 2014
Povidone iodine ointment and solutions are available in the market under various popular brands such as Betadine and Wokadine.
Nestle's cumin extract patent bid raises hacklesRediff.com8 Jan 2014
Company claims new use for kala jeera extract, provoking alarmed campaigners here and abroad; says reaction not based on facts.
Wockhardt's Shendra unit set for key US testRediff.com7 Jan 2014
If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.
Repackaged drugs likely to be labelled 'new'Rediff.com2 Jan 2014
Roadblocks ahead as these medicines could face new clinical tests, more scrutiny
US FDA likely to inspect new Visakhapatnam arm of Divi's Labs in JanRediff.com31 Dec 2013
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
Local drug makers worried as regulators start working togetherRediff.com26 Dec 2013
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
Pharma firms might resume sales of analgin-based drugsRediff.com24 Dec 2013
The Drugs Controller General of India is considering the recommendations of its advisory body to revoke the suspension of the sale of analgin-based medicines in the country.